|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
A recent increase in allergic disorders has coincided with a decrease in infections, including tuberculosis.
Although an inverse association between tuberculin responses and atopic disorders was reported, it was
not known how T-helper (Th)1-biased immune responses to Mycobacterium tuberculosis influenced Th2-dominant responses to allergens. We examined whether M. tuberculosis could modulate ovalbumin
(OVA)-induced eosinophilic inflammation in the murine trachea in a manner that transcended the barrier
of antigen specificity. We found that CD4+ T cells primed with OVA in complete Freund's adjuvant
(CFA) inhibited OVA-induced tracheal eosinophilia through interferon (IFN)-
secretion. Immunization
with an irrelevant antigen in CFA or with OVA in incomplete Freund's adjuvant failed to induce suppressor cells. In vitro experiments confirmed that both M. tuberculosis and OVA (as opposed to either one
alone) were necessary to evoke polarized development toward a Th1-like phenotype through interleukin-12 secretion. These results indicate that exposure to an allergen along with M. tuberculosis switches development of allergen-specific T cells toward a Th1 phenotype, which, in turn, downregulates allergic manifestations in an antigen-specific manner. The possible implications of these results are discussed in the
context of the causal relationship between a decrease in tuberculosis and an increase in allergic disorders.
| |
Introduction |
|---|
|
|
|---|
Allergic disorders, such as bronchial asthma, atopic dermatitis, and allergic rhinitis, have been increasing rapidly in developed countries (1). Coincidentally in these areas, infections with Mycobacterium tuberculosis have been declining (5). A recent report has provided convincing evidence for an inverse association between tuberculin responses and atopic disorders (6).
T lymphocytes have been implicated in the pathogenesis of allergic disease (7). Moreover, it has been suggested
that cytokines elaborated from type-2 CD4+ T-helper
(Th2) cells, including interleukin (IL)-4 and IL-5, induce
immunoglobulin (Ig)E synthesis as well as activation and recruitment of eosinophils (8). Type-1 CD4+ T helper (Th1)
cells are required for protection from infection by microorganisms, particularly those that grow in the cytoplasm of
infected cells (9). Interferon (IFN)-
secreted from Th1 cells activates macrophages, leading to the inhibition and
killing of phagocytosed pathogenic microorganisms, which
otherwise survive by evading digestive elimination in unactivated macrophages (10). It is interesting that these
two types of CD4+ T cells act in a reciprocally inhibitory
manner through the secretion of type-specific cytokines
(8). The concurrence of an increase in allergic diseases mediated by Th2 cells and a decrease in infection with M. tuberculosis that activates Th1 cells, therefore appears to be
more than a mere coincidence. The notion of a causal relation between these two trends is, however, challenged by
the antigen-specific nature of the immune system; allergen-specific Th2 cells and M. tuberculosis-specific Th1
cells are not expected to mutually cross-regulate each other.
We examined the modulation by M. tuberculosis of eosinophilic inflammation evoked by a soluble allergen. M. tuberculosis switched the development of ovalbumin (OVA)-specific CD4+ T cells from a Th2 to a Th1 phenotype and inhibited airway eosinophilic responses. Essential to this skewing effect was the concurrent presence of M. tuberculosis with the allergen at the time of priming. In this article we report our findings and consider their possible implications in the context of the notion that a decrease in tuberculosis might be a causal factor in an increase in allergic disorders.
| |
Materials and Methods |
|---|
|
|
|---|
Animals and Immunization
BALB/c mice and BALB/c mice transgenic (tg) for T-cell receptor (TCR) specific for OVA (13) were bred in our animal facility and were used at 5 to 10 wk of age. For the induction of airway eosinophilic inflammation, BALB/c mice were immunized intraperitoneally with 10 µg of OVA (grade V; Sigma Chemical Co., St. Louis, MO) precipitated with 4 mg of aluminum hydroxide (alum) in 200 µl of phosphate-buffered saline (PBS) three times weekly. For one group of mice, the third dose consisted of 10 µg of OVA emulsified in complete Freund's adjuvant (CFA) containing H37Ra M. tuberculosis (Difco Laboratories, Detroit, MI) rather than OVA/alum. For adoptive cell transfer and in vitro culture experiments, BALB/c mice received a footpad injection of 100 µg of OVA emulsified in CFA or incomplete Freund's adjuvant (IFA; Difco) or of hen egg lysozyme (HEL; Wako Chemical Industries Ltd., Osaka, Japan) or PBS in CFA.
Antigen-Induced Eosinophilia in the Trachea
We have detailed our methods previously (14). In brief, 1 wk after the last intraperitoneal dose of OVA/alum, sensitized mice were lightly anesthetized with pentobarbital (Abbott Laboratories, North Chicago, IL), and 10 µg of OVA in 10 µl of PBS was instilled directly into the surgically exposed trachea. After 2 d, the excised trachea was fixed in 10% formalin and frozen in OCT compound (Miles Laboratories, Naperville, IL). Cryosections (7 µm thick) of the frozen tissue were stained with Diff-Quik (International Reagents Corp., Kobe, Japan). The numbers of eosinophils infiltrating the submucosal tissue of the trachea were determined by light microscopy. The perimeter of the basement membrane of the trachea was measured with an MCID image analyzer (Imaging Research Inc., St. Catherines, ON, Canada). For every trachea, six to eight sections were used for counting, each of which was separated from the adjacent sections by more than 70 µm. Results were converted to the number of eosinophils per 1-mm basement membrane length. Data were expressed as means ± standard error of the mean (SEM) for four to seven mice in each group. Each experiment was repeated at least twice. Student's t test was employed in the analysis of results.
Adoptive Transfer of Antigen-Primed Lymph Node Cells
Seven days after footpad immunization, 3 × 106 popliteal lymph node (LN) cells were injected intravenously into OVA/alum-sensitized BALB/c mice, either with or without fractionation. Between 1 and 2 h after cell transfer, the mice received an intratracheal dose of OVA as described below.
Fractionation of T Cells
Spleen or LN cells were preincubated with PBS, anti-CD4 (Gk1.5) (15), or anti-CD8 (3.155) (16) monoclonal antibodies (mAbs) for 1 h at 4°C. They were allowed to react with antimouse Ig (Caltag, South San Francisco, CA) immobilized on plastic plates (Falcon, Lincoln Park, NJ) for 1 h at 4°C, and nonadherent cells were recovered as T cells, CD8+ T cells, and CD4+ T cells, respectively. Both mAbs were used at a 1:1,000 dilution of the ascites form. Efficiency of depletion was determined by flow cytometry to be greater than 95%.
In Vivo Neutralization with mAbs
For in vivo treatment with mAbs, 30 µl of the ascites form
of neutralizing antibody to IFN-
(R4-6A2; rat IgG1) (17)
or an isotype-matched control antibody that recognizes
CD25 (PC61-5-3) (18) was administered intraperitoneally
to OVA/alum-sensitized BALB/c mice at the time of cell
transfer. These two hybridoma cell lines were obtained from
the American Type Culture Collection (ATCC) (Rockville,
MD), and ascites were raised in BALB/c nu/nu mice.
In Vitro Stimulation of BALB/c LN CD4+ T Cells
LN cells from BALB/c mice primed with OVA or HEL
emulsified in CFA or IFA were enriched for CD4+ T cells
as described above. Spleen cells from unimmunized
BALB/c mice were treated with mitomycin C (50 µg/ml;
Wako) for 30 min and then used as antigen-presenting
cells (APCs). After coculture of 105 CD4+ T cells and 2.5 × 105 APCs with 1 mg of OVA/ml for 2 d in 96-well plates,
culture supernatants were assayed for IFN-
and IL-4.
In Vitro Stimulation of Anti-OVA TCR tg T Cells with M. tuberculosis
Spleen cells (2.5 × 106) from unimmunized anti-OVA
TCR tg mice were cultured with OVA (100 µg/ml) in the
presence or absence of heat-killed M. tuberculosis (1 µg/ml;
Aoyama B strain, kindly provided by Taeko Yokochi-Fukuda, University of Tokyo, Tokyo, Japan) in 12-well
plates for 3 d. Anti-IL-12 mAb (Genzyme Co., Cambridge, MA), isotype-matched control mAb (rat IgG2a;
PharMingen, San Diego, CA), and recombinant murine
IL-12 (Genzyme) were added at graded concentrations at
the initiation of culture. The cells were cultured in fresh
medium for another 3 d. Viable lymphocytes were recovered from the interface by Ficoll-Paque (Pharmacia Biotech AB, Uppsala, Sweden) density-gradient centrifugation and were enriched for CD4+ T cells as described
above. Next, 104 CD4+ tg T cells were cultured with 2 × 105 APCs in the presence or absence of OVA (1 mg/ml) in
96-well plates. Anti-CD4 or anti-CD8 mAb was added to
cultures at a 1:3,000 dilution of ascites form. After 2 d, culture supernatants were assayed for IFN-
and IL-4.
Assays for Cytokines
The concentrations of IFN-
and IL-4 in culture supernatants were determined using enzyme-linked immunosorbent assay (ELISA) with paired mAbs to IFN-
and IL-4
(PharMingen) according to the manufacturer's recommendations. Tetramethylbenzidine reagent (Kierkegaard & Perry Laboratories, Gaithersburg, MD) was used for color
development, and optical densities determined at 450 nm
were converted to concentrations (nanograms per milliliter) according to the standard curve obtained with titrated
concentrations of mouse IFN-
(PharMingen) and IL-4 (Genzyme). Student's t test was employed in the analysis
of results.
| |
Results |
|---|
|
|
|---|
Low Efficacy of CFA as an Adjuvant for Antigen-Induced Airway Eosinophilia
We first compared the efficacy of CFA and alum as adjuvants for the induction of antigen-induced tracheal eosinophilia. Tracheal eosinophilia was induced by intratracheal instillation of OVA into BALB/c mice sensitized with OVA (Figure 1). Mice immunized with three doses of OVA/alum developed 13.3 ± 2.3 eosinophils (mean ± SEM) in the trachea upon intratracheal instillation of OVA. In mice immunized with two doses of OVA/alum and one dose of OVA in M. tuberculosis-containing CFA, fewer eosinophils (3.8 ± 1.2) infiltrated the trachea. Thus, CFA was a less effective adjuvant than alum for the induction of eosinophilic inflammation.
|
Antigen-Specific and M. tuberculosis-Dependent Induction of Suppressor Cells
To examine whether immunization with OVA in CFA induced eosinophilia-inhibiting cells, we adoptively transferred regional LN cells draining OVA/CFA-injected footpads (Figure 2). Eosinophilic responses in the tracheal submucosa were severely impaired by adoptive transfer of OVA/CFA-primed LN cells (Figure 2, bar 2), indicating the induction of suppressor cells. M. tuberculosis in CFA was essential for the induction of the suppressor cells; LN cells primed with OVA in IFA, which differed from CFA only in its lack of M. tuberculosis, failed to suppress eosinophilia (Figure 2, bar 3). The suppression was antigen-specific, because LN cells primed with PBS/CFA (data not shown) or with an irrelevant antigen HEL in CFA (Figure 2, bar 4) failed to suppress OVA-induced eosinophilic responses. Higher numbers of LN cells (107) from OVA/ IFA- or HEL/CFA-primed BALB/c mice exerted no effect on eosinophilia (data not shown). Thus, immunization with a soluble antigen together with CFA induced suppressor cells whose inhibitory specificity was skewed toward allergic responses evoked by the same antigen as used for immunization.
|
CD4+ T Cells as the Active Suppressor Cells
We examined the phenotype of CFA-induced suppressor cells. The control response was inhibited by adoptive transfer of OVA/CFA-primed LN cells enriched for T cells (Figure 3, bar 2). A similar level of suppression was observed upon the transfer of a CD4+ T cell-enriched fraction (Figure 3, bar 3), whereas a T-cell population depleted of CD4+ cells failed to suppress eosinophilic inflammation (Figure 3, bar 4). These results indicate that the active suppressor cells were CD4+ T cells.
|
Neutralization of OVA/CFA-Induced
Suppressor Cells by Anti-IFN-
mAb
To examine whether IFN-
was involved in the suppression of eosinophilia, we injected neutralizing anti-IFN-
mAb intraperitoneally into OVA/alum-sensitized mice at
the time of adoptive transfer of OVA/CFA-primed LN
cells. The inhibition of OVA-induced eosinophilia was abrogated by neutralizing anti-IFN-
mAb (Figure 4, bar 3), but not by an isotype-matched control antibody specific
for CD25 (Figure 4, bar 4). Thus, IFN-
elaborated from
CFA/OVA-primed cells was the essential cytokine involved in the downregulation of eosinophilia.
|
M. tuberculosis-Induced Development of
IFN-
-secreting CD4+ T Cells
To substantiate the above findings, we examined IFN-
and IL-4 production from LN CD4+ T cells of the BALB/c
mice immunized with OVA in CFA or IFA (Figure 5).
Cells produced low levels of cytokines when stimulated
with low concentrations of OVA (< 1 to 10 µg/ml). Cells
from OVA/CFA-immunized mice produced IFN-
in
preference to IL-4 in response to higher doses of OVA
(100 to 1,000 µg/ml). Conversely, OVA/IFA-immunized cells produced high levels of IL-4 in comparison with IFN-
.
Thus, the presence of M. tuberculosis at the time of immunization with OVA caused a skewing toward predominantly IFN-
-producing cells. Reverse transcriptase-polymerase chain reaction also demonstrated that, compared
with OVA/IFA, OVA/CFA enhanced expression of IFN-
and decreased expression of IL-4 in LN cells (data not
shown). The LN cells primed with HEL/CFA produced little IFN-
or IL-4 upon OVA stimulation; thus M. tuberculosis alone did not promote the development of IFN-
-
secreting CD4+ T cells.
|
Skewing the Development of CD4+ T Cells
toward IFN-
-Secreting Cells by OVA
and M. tuberculosis
To verify the essential requirement for OVA and M. tuberculosis in the skewing of CD4+ T-cell development toward OVA-specific Th1 cells, we examined the differentiation of CD4+ T cells precultured in the presence of OVA
and/or M. tuberculosis (Figure 6A). When CD4+ T cells
from unimmunized anti-OVA TCR tg mice were precultured with OVA in the absence of M. tuberculosis, they exhibited Th2-dominant responses: high-level IL-4 and low-level IFN-
production (Figure 6A, middle bar). In sharp
contrast, the same tg cells stimulated in the presence of
both OVA and M. tuberculosis showed predominantly Th1 differentiation, with high-level IFN-
and low-level
IL-4 production (Figure 6A, bottom bar). In the absence
of OVA in restimulation cultures, levels of IFN-
or IL-4
were < 0.2 ng/ml (data not shown). These results indicate
that M. tuberculosis induces the biased development of
CD4+ T cells toward a Th1 phenotype which otherwise defaulted to a Th2 response. CD4+ tg T cells precultured
with M. tuberculosis but without OVA did not produce
substantial levels of IFN-
and IL-4 (Figure 6A, top bar).
This finding offers further support for the requirement of
the concomitant presence of both OVA and M. tuberculosis for the skewing toward OVA-specific Th1 cells. Both
IFN-
production and IL-4 production were completely
inhibited by anti-CD4 mAb in restimulation cultures,
whereas anti-CD8 mAb had no effect; these results confirmed that CD4+ but not CD8+ T cells produce these cytokines (Figure 6B).
|
IL-12-Mediated Switch toward Th1 Development in the Presence of M. tuberculosis
We examined whether IL-12 mediated a switch from Th2 to Th1 development. CD4+ tg T cells precultured in the presence of M. tuberculosis and OVA displayed a Th1-dominant phenotype (Figures 7A and 7B). When graded doses of anti-IL-12 mAb were included in precultures, the CD4+ T cells exhibited a Th2 phenotype upon restimulation with OVA. Isotype-matched control mAb had no effect. The effect of anti-IL-12 mAb on the bias toward Th2 development was reversed by excess amounts of IL-12 (Figures 7C and 7D): 1 ng of IL-12/ml neutralized the switching effect of anti-IL-12 mAb with reversion to Th1-dominant responses, which was almost comparable with control responses. These results indicate that IL-12 mediates a switch from a Th2 to a Th1 phenotype.
|
| |
Discussion |
|---|
|
|
|---|
This study was prompted by a recent increase in allergic disorders paralleled by a decrease in various infections, including tuberculosis. Recent reports have provided convincing evidence for an inverse association between tuberculin responses and atopic disorders and have suggested that exposure and response to M. tuberculosis inhibit atopic disorders (6). The issue of how Th1 cells induced by M. tuberculosis can regulate Th2 cells against distinct antigens has not previously been addressed. We examined mechanisms by which M. tuberculosis might modulate OVA-induced eosinophilic inflammation in the murine trachea, transcending the barrier of antigen specificity.
In our experimental model, M. tuberculosis was indispensable in the induction of IFN-
-producing anti-OVA
Th1 cells. LN cells from mice immunized with OVA in
CFA but not in IFA inhibited antigen-induced tracheal
eosinophilia (Figure 2). The inhibitory activity of the transferred cells paralleled the production of IFN-
from
these cells, because LN cells from mice immunized with
OVA/CFA but not OVA/IFA produced IFN-
in preference to IL-4 (Figure 5). Anti-IFN-
mAb reversed the inhibitory effect of the transferred cells on eosinophilic inflammation (Figure 4). Additional evidence came from an
in vitro experiment in which IFN-
-secreting Th1-like cells
were found to be dominant in the presence but not the absence of M. tuberculosis bacilli (Figure 6). Thus, M. tuberculosis plays a causative role in a bias toward the development of a Th1-dominant phenotype among CD4+ T cells
that otherwise default to a Th2-dominant phenotype.
Tuberculous infection per se favors the induction of a
Th1 response to M. tuberculosis (19). Is M. tuberculosis
sufficient for the induction of Th1-dominant responses to
any antigens? Because antigen specificity is considered a
basic characteristic of the immune system, a Th2 response
to a certain antigen and a Th1 response to an irrelevant
antigen are expected to occur independently. In fact,
transfer of LN cells from OVA/CFA-immunized mice inhibited OVA-induced eosinophilic responses, whereas LN
cells from PBS/CFA- or HEL/CFA-primed mice failed
to do so (Figure 2). LN cells from mice immunized with
OVA/CFA but not HEL/CFA produced IFN-
in response to OVA (Figure 5). CD4+ tg T cells cultured with
M. tuberculosis alone did not manifest anti-OVA Th1 activities, whereas the concomitant presence of OVA and
M. tuberculosis successfully induced OVA-specific Th1 cells (Figure 6). Thus, M. tuberculosis did not skew parallel and
independent responses to irrelevant antigens toward a
Th1-dominant phenotype, but instead selectively induced
Th1 responses to a soluble antigen that was in close proximity to M. tuberculosis.
Our experiments reported in this paper revealed two
possible mechanisms by which M. tuberculosis ameliorates
Th2-mediated allergic responses. First, M. tuberculosis
skewed the development of anti-OVA CD4+ T cells toward a Th1-dominant phenotype. OVA alone induced
Th2-dominant responses in vivo and in vitro in the absence
of M. tuberculosis, whereas the concomitant presence of
M. tuberculosis skewed anti-OVA responses toward a
Th1-dominant phenotype (Figures 2, 5, and 6), thereby
leading to an increase in the ratio of Th1 cells to Th2 cells.
Second, newly generated OVA-specific Th1 cells inhibited the function of preexisting Th2 cells mediating eosinophilic responses (Figures 2-4). Because the inhibition of
Th2 cells by Th1 cells occurred in an antigen-specific manner (Figure 2), dysfunction of the immune response to
other antigens, such as pathogenic microorganisms, could
be avoided. IFN-
delivered inhibitory signals from Th1 cells to Th2 cells (Figures 4 and 5) (23).
The skewing toward Th1-dominant anti-OVA responses caused by the presence of both M. tuberculosis and OVA was mediated by IL-12 (Figure 7). In vivo IL-12 treatment has been reported to abrogate antigen-induced pulmonary eosinophilia (24). However, signals other than IL-12 appear to be necessary for efficient in vitro Th1 development because M. tuberculosis in the absence of OVA failed to induce anti-OVA Th1 cells (Figure 6). We could not identify the cell sources secreting IL-12 in the present studies. IL-12 is known to be secreted from APCs such as dendritic cells and macrophages that phagocytose intracytoplasmic microorganisms (including M. tuberculosis) and to induce differentiation into Th1 cells (9, 27). In light of these findings, APCs that phagocytose, process, and present both M. tuberculosis and OVA are prime candidates for the cells responsible for IL-12 secretion. If M. tuberculosis and OVA were taken up by distinct APCs, IL-12 secreted from M. tuberculosis-laden APCs would not reach anti-OVA Th cells efficiently. One of the possible circumstances in which IL-12 would efficiently affect anti-OVA Th cells would be that in which OVA-specific Th cells recognized through TCR antigens on and were targeted to the IL-12-secreting APCs presenting M. tuberculosis and OVA. Phagocytosis and antigen presentation of both M. tuberculosis and OVA by the same or neighboring APC(s) are likely to occur when OVA is in temporal and spatial proximity to M. tuberculosis. Thus, the simultaneous presence of M. tuberculosis and OVA is an important factor in the facilitation of anti-OVA Th1 responses.
In view of the recent decrease in mycobacterial infections and the parallel increase in allergic disorders, the above findings could be interpreted as follows (Figure 8). Airway inhalation of allergens (e.g., house dust mites) favors the activation of Th2-dominant responses (31), whereas exposure to intracytoplasmic microorganisms (e.g., M. tuberculosis) tends to activate Th1-dominant responses (9, 19). If M. tuberculosis were more prevalent and were repeatedly inhaled, exposures to possible allergens and M. tuberculosis would be more likely to occur simultaneously. Allergens and nearby M. tuberculosis cells would tend to be engulfed, processed, and presented by the same or nearby APC(s) to which both M. tuberculosis- specific and allergen-specific T cells were targeted. APCs engulfing M. tuberculosis would elaborate IL-12, which would facilitate differentiation into Th1 cells specific for allergens as opposed to the usual default to a Th2 response (31). Essential to this effect of IL-12 would be the proximity of allergen-specific T cells to APCs that phagocytosed M. tuberculosis and secreted IL-12. Allergen-specific Th1 cells induced in this manner would in turn inhibit preexisting Th2 cells with the same antigen specificity and thereby ameliorate Th2-mediated allergic manifestations.
|
The skewing of allergen-specific Th cells toward Th1 responses required concomitant exposure to allergens and M. tuberculosis. More important, simultaneous inhalation of allergens and M. tuberculosis was not always necessary for regulation of Th2-mediated allergies. Even during Th2-mediated allergic responses, newly induced Th1 cells inhibited the preexisting Th2 cells. When M. tuberculosis was more prevalent, it was more likely that immune systems would encounter allergens and M. tuberculosis simultaneously and that the induction of allergen-specific Th1 cells would be followed by inhibition of Th2 cells. Thus, it is tempting to speculate that when M. tuberculosis was more prevalent, allergic reactions were more likely to be inhibited.
Recent clinical studies have dealt with the relation between tuberculous infection, bacillus Calmette-Guerin
(BCG), and atopy. Shirakawa and colleagues reported an
inverse association between tuberculin responses and atopic
disorders, and concluded that exposure and response to
M. tuberculosis might inhibit these disorders (6). Alm and
coworkers investigated whether BCG vaccination against
tuberculosis influenced the development of atopy and found that early BCG vaccination in children with atopic heredity did not affect the development of atopic diseases (35).
Their study is in accord with our notion that M. tuberculosis given separately from allergen fails to cause a bias toward Th1 responses. More recently, Erb and associates
demonstrated that BCG infection of the lung strongly inhibits the development of airway eosinophilia (36). They
showed that the BCG infection-induced inhibition of airway eosinophilia was strongly inhibited in IFN-
receptor- deficient mice. These results are in agreement with ours
with respect to the inhibitory role of IFN-
in M. tuberculosis-induced regulation of eosinophilia. They also showed
that intranasal infection was superior to intraperitoneal or
subcutaneous infection in its ability to reduce airway eosinophilia, and they suggested that BCG should be administered directly into the lung. We reason that the efficient inhibition of lung eosinophilia was due to the simultaneous presence of BCG and OVA in the lung and not necessarily
to the direct administration of BCG into the lung. In view
of our observations, we speculate that subcutaneous immunization with BCG and allergens would efficiently induce allergen-specific Th1 cells, which in turn would inhibit allergic responses.
In the present study we inoculated M. tuberculosis via an intraperitoneal or subcutaneous approach. This approach is likely to be relevant to the ordinal infectious route of pulmonary tuberculosis with respect to how antigens are processed and presented to T cells by APC. Holt reported that the most potent APC in the lung was dendritic cells, which acquired the fully potent ability to stimulate T cells after migration to and activation in regional lymphoid tissues (37), and these features were shared with dendritic cells in tissues outside the respiratory tract (38). Thus, regardless of the route of M. tuberculosis entry, the ensuing processing and presentation to T cells of the bacilli would proceed in a similar manner.
CFA containing killed M. tuberculosis is commonly
used for activation of CD4+ cells and production of antibodies, whereas M. tuberculosis is an intracellular pathogen and roles for CD8+ T cells in controlling tuberculous
infection are also well demonstrated in mice infected with
live bacilli (39). Because CD8+ T cells secrete Th1-like
cytokines such as IFN-
, these cells could be a potential
regulator of Th2 cells. Failure of CD8+ T cells to exert inhibitory effects on tracheal eosinophilia (Figure 3) might
reflect preferential activation of CD4+ T cells by killed
M. tuberculosis inoculated as a form of CFA. The role of
CD8+ T cells as a regulator of allergic responses needs further evaluation.
In summary, we examined the effect of M. tuberculosis on in vivo and in vitro Th2-mediated responses, and we discussed the mechanisms by which M. tuberculosis may ameliorate allergic diseases. We hope that these findings will be applicable to the development of antigen-specific vaccines useful in therapy for allergic disorders such as bronchial asthma.
| |
Footnotes |
|---|
Abbreviations: aluminum hydroxide, alum; antigen-presenting cell, APC; bacillus Calmette-Guerin, BCG; complete Freund's adjuvant, CFA; hen egg lysozyme, HEL; incomplete Freund's adjuvant, IFA; interferon, IFN; immunoglobulin, Ig; interleukin, IL; lymph node, LN; monoclonal antibody, mAb; ovalbumin, OVA; phosphate-buffered saline, PBS; T-cell receptor, TCR; transgenic, tg; T-helper, Th.
(Received in original form August 26, 1998 and in revised form November 18, 1998).
| |
References |
|---|
|
|
|---|
1. Bräbäck, L., A. Breborowiez, S. Dreborg, A. Knutsson, H. Pieklik, and B. Björksten. 1994. Atopic sensitization and respiratory symptoms among Polish and Swedish school children. Clin. Exp. Allergy 26: 621-623 .
2. Seaton, A., D. J. Godden, and K. Brown. 1994. Increase in asthma: a more toxic environment or a more susceptible population? Thorax 49: 171-174 [Medline].
3. Gergen, P. J., and K. B. Weiss. 1995. Epidemiology of asthma. In Asthma and Rhinitis. W. W. Busse and S. T. Holgate, editors. Blackwell Scientific Publications, Boston, MA. 15-31.
4.
Cookson, W. O. C. M., and
M. F. Moffatt.
1997.
Asthma: an epidemic in the
absence of infection?
Science
275:
41-42
5. Glassroth, J., A. G. Robins, and D. Snider Jr.. 1980. Tuberculosis in the 1980s. N. Engl. J. Med. 302: 1441-1447 [Medline].
6.
Shirakawa, T.,
T. Enomoto,
S. Shimazu, and
J. M. Hopkin.
1997.
The inverse association between tuberculin responses and atopic disorder.
Science
275:
77-80
7. Corrigan, C. J., and A. B. Kay. 1992. T cells and eosinophils in the pathogenesis of asthma. Immunol. Today 13: 501-507 [Medline].
8. Mosmann, T. R., J. H. Schumacher, N. F. Street, R. Budd, A. O'Garra, T. A. T. Fong, M. W. Bond, K. W. M. Moore, A. Sher, and D. F. Fiorentino. 1991. Diversity of cytokine synthesis and function of mouse CD4+ T cells. Immunol. Rev. 123: 209-229 [Medline].
9.
Hsieh, C.,
S. E. Macatonia,
C. S. Tripp,
S. F. Wolf,
A. O'Garra, and
K. M. Murphy.
1993.
Development of Th1 CD4+ T cells through IL-12 produced
by Listeria-induced macrophages.
Science
260:
547-579
10.
Murray, H. W.,
B. Y. Rubin, and
C. D. Rothermel.
1983.
Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes: evidence that interferon-
is the activating lymphokine.
J. Clin. Invest.
72:
1506-1510
.
11. Titus, R. G., A. Kelso, and J. A. Louis. 1984. Intracellular destruction of Leishmania tropica by macrophages activated with macrophage activating factor/interferon. Clin. Exp. Immunol. 55: 157-165 [Medline].
12.
Murray, H. W.,
J. J. Stern,
K. Welte,
B. Y. Rubin,
S. M. Carriero, and
C. F. Nathan.
1987.
Experimental visceral leishmaniasis: production of interleukin 2 and interferon-
, tissue immune reaction, and response to treatment
with interleukin 2 and interferon-
.
J. Immunol.
138:
2290-2297
[Abstract].
13. Sato, T., T. Sasahara, Y. Nakamura, T. Osaki, T. Hasegawa, T. Tadakuma, Y. Arata, Y. Kumagai, M. Katsuki, and S. Habu. 1994. Naive T cells can mediate delayed-type hypersensitivity response in T cell receptor transgenic mice. Eur. J. Immunol. 24: 1512-1516 [Medline].
14.
Haneda, K.,
K. Sano,
G. Tamura,
T. Sato,
S. Habu, and
K. Shirato.
1997.
TGF-
induced by oral tolerance ameliorates experimental tracheal eosinophilia.
J. Immunol
159:
4484-4490
[Abstract].
15. Wilde, D. B., P. Marrack, J. Kappler, D. P. Dialynas, and F. W. Fitch. 1983. Evidence implicating L3T4 in class II MHC antigen reactivity: monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J. Immunol. 131: 2178-2183 [Abstract].
16. Sarmiento, M., A. L. Glasebrook, and F. W. Fitch. 1980. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt-2 antigen block T cell-mediated cytolysis in the absence of complement. J. Immunol. 125: 2665-2672 [Abstract].
17.
Spitalny, G. L., and
E. A. Havell.
1984.
Monoclonal antibody to murine
gamma interferon inhibits lymphokine-induced antiviral and macrophage
tumoricidal activities.
J. Exp. Med.
159:
1560-1565
18.
Zubler, R. H.,
J. W. Lowenthal,
F. Erard,
N. Hashimoto,
R. Devos, and
H. R. MacDonald.
1984.
Activated B cells express receptors for, and proliferate in response to, pure interleukin 2.
J. Exp. Med.
160:
1170-1183
19.
Haanen, J. B. A. G.,
R. W. Malefijt,
P. C. M. Res,
E. M. Kraakman,
T. H. M. Ottenhoff,
R. R. P. Vries, and
H. Spits.
1991.
Selection of a human T
helper type 1-like T cell subset by mycobacteria.
J. Exp. Med.
174:
583-592
20.
Singh, I. G.,
R. Mukherjee,
G. P. Talwar, and
S. H. E. Kaufmann.
1992.
In
vitro characterization of T cells from Mycobacterium w-vaccinated mice.
Infect. Immun.
60:
257-263
21.
Barnes, P. F.,
S. Lu,
J. S. Abrams,
E. Wang,
M. Yamamura, and
R. L. Modlin.
1993.
Cytokine production at the site of disease in human tuberculosis.
Infect. Immun.
61:
3482-3489
22.
Robinson, D. S.,
S. Ying,
I. K. Taylor,
A. Wangoo,
D. M. Mitchell,
A. B. Kay,
Q. Hamid, and
R. J. Shaw.
1994.
Evidence for a Th1-like bronchoalveolar T-cell subset and predominance of interferon-
gene activation in
pulmonary tuberculosis.
Am. J. Respir. Crit. Care Med.
149:
989-993
[Abstract].
23. Gajewski, T. F., and F. W. Fitch. 1988. Anti-proliferative effect of IFN-gamma in immune regulation: IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J. Immunol. 140: 4245-4252 [Abstract].
24.
Gavett, S. H.,
D. J. O'Hearn,
X. Li,
S. K. Huang,
F. D. Finkelman, and
M. Wills-Karp.
1995.
Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice.
J. Exp.
Med.
182:
1527-1536
25. Kips, J. C., G. J. Brusselle, G. F. Joos, R. A. Peleman, J. H. Tavernier, R. R. Devos, and R. A. Pauwels. 1996. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness in mice. Am. J. Respir. Crit. Care Med. 153: 535-539 [Abstract].
26. Sur, S., J. Lam, P. Bouchard, A. Sigounas, D. Holbert, and W. J. Metzger. 1996. Immunomodulatory effects of IL-12 on allergic lung inflammation depend on timing of doses. J. Immunol. 157: 4173-4180 [Abstract].
27.
Reiner, S. L.,
S. Zheng,
Z. E. Wang,
L. Stowring, and
R. M. Locksley.
1994.
Leishmania promastigotes evade IL-12 induction by macrophages and
stimulate a broad range of cytokines from CD4+ T cells during initiation of
infection.
J. Exp. Med.
179:
447-456
28.
Flesch, I. E.,
J. H. Hess,
S. Huang,
M. Aguet,
J. Rothe,
H. Bluethmann, and
S. H. Kaufmann.
1995.
Early IL-12 production by macrophages in response to mycobacterial infection depends on interferon
and tumor necrosis factor
.
J. Exp. Med.
181:
1615-1621
29. Aliberti, J. C., M. A. Cardoso, G. A. Martins, R. T. Gazzinelli, L. Q. Vieira, and J. S. Silva. 1996. IL-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes. Infect. Immun. 64: 1961-1967 [Abstract].
30. Macatonia, S. E., N. A. Hosken, M. Litton, P. Vieira, C. S. Hsieh, J. A. Culpepper, M. Wysocka, G. Trinchieri, K. M. Murphy, and A. O'Garra. 1995. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J. Immunol. 154: 5071-5079 [Abstract].
31. Wiergnga, E. A., M. Snoek, C. Groot, I. Chretien, J. D. Bos, H. M. Jansen, and M. L. Kapsenberg. 1990. Evidence for compartmentalization of functional subsets of CD4+ T lymphocytes in atopic patients. J. Immunol. 144: 4651-4656 [Abstract].
32. Yssel, H., K. E. Johnson, P. V. Schneider, J. Wideman, A. Terr, R. Kastelein, and J. E. Vries. 1992. T cell activation-inducing epitopes of the house dust mite allergen Der pI. Proliferation and lymphokine production patterns by Der pI-specific CD4+ T cell clones. J. Immunol. 148: 738-745 [Abstract].
33. Ebner, C., Z. Szepfalusi, F. Ferreira, A. Jilet, R. Valenta, P. Parronchi, E. Maggi, S. Romangnani, O. Scheiner, and D. Kraft. 1993. Identification of multiple T cell epitopes on Bet v I, the major birch pollen allergen, using specific T cell clones and overlapping peptides. J. Immunol. 150: 1047-1054 [Abstract].
34.
Parronchi, P.,
D. Macchia,
M. P. Piccinni,
P. Biswas,
C. Simonelli,
E. Maggi,
M. Ricci,
A. A. Ansari, and
S. Romagnani.
1991.
Allergen- and bacterial
antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production.
Proc. Natl. Acad. Sci. USA
88:
4538-4542
35. Alm, J. S., G. Lilja, G. Pershagen, and A. Scheynius. 1997. Early BCG vaccination and development of atopy. Lancet 350: 400-403 [Medline].
36.
Erb, K. J.,
J. W. Holloway,
A. Sobeck,
H. Moll, and
G. LeGros.
1998.
Infection of mice with Mycobacterium bovis-bacillus Calmette-Guérin (BCG)
suppresses allergen-induced airway eosinophilia.
J. Exp. Med.
187:
561-569
37. Holt, P. G.. 1993. Regulation of antigen-presenting cell function(s) in lung and airway tissues. Eur. Respir. J. 6: 120-129 [Abstract].
38. Steinman, R. M.. 1993. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9: 271-296 [Medline].
39. Orme, I. M.. 1987. The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. J. Immunol. 138: 293-298 [Abstract].
40.
Müller, I.,
S. P. Cobbold,
H. Waldmann, and
S. H. E. Kaufmann.
1987.
Impaired resistance to Mycobacterium tuberculosis infection after selective in
vivo depletion of L3T4+ and Lyt-2+ T cells.
Infect. Immun.
55:
2037-2041
41.
Flynn, J. L.,
M. M. Goldstein,
K. J. Triebold,
B. Koller, and
B. R. Bloom.
1992.
Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection.
Proc. Natl.
Acad. Sci. USA
89:
12013-12017
42.
Tascon, R. E.,
E. Stavropoulos,
K. V. Lukacs, and
M. J. Colston.
1998.
Protection against Mycobacterium tuberculosis infection by CD8+ T cells requires the production of gamma interferon.
Infect. Immun.
66:
830-834
This article has been cited by other articles:
![]() |
M. M. Anis, S. A. Fulton, S. M. Reba, C. V. Harding, and W. H. Boom Modulation of Naive CD4+ T-Cell Responses to an Airway Antigen during Pulmonary Mycobacterial Infection Infect. Immun., May 1, 2007; 75(5): 2260 - 2268. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Cannarile, F. Fallarino, M. Agostini, S. Cuzzocrea, E. Mazzon, C. Vacca, T. Genovese, G. Migliorati, E. Ayroldi, and C. Riccardi Increased GILZ expression in transgenic mice up-regulates Th-2 lymphokines Blood, February 1, 2006; 107(3): 1039 - 1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sano, H. Shirota, T. Terui, T. Hattori, and G. Tamura Oligodeoxynucleotides Without CpG Motifs Work as Adjuvant for the Induction of Th2 Differentiation in a Sequence-Independent Manner J. Immunol., March 1, 2003; 170(5): 2367 - 2373. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. Hylkema, W. Timens, M. Luinge, N. van der Werf, and M. O. Hoekstra The Effect of Bacillus Calmette-Guerin Immunization Depends on the Genetic Predisposition to Th2-Type Responsiveness Am. J. Respir. Cell Mol. Biol., August 1, 2002; 27(2): 244 - 249. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Shirota, K. Sano, N. Hirasawa, T. Terui, K. Ohuchi, T. Hattori, and G. Tamura B Cells Capturing Antigen Conjugated with CpG Oligodeoxynucleotides Induce Th1 Cells by Elaborating IL-12 J. Immunol., July 15, 2002; 169(2): 787 - 794. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Shirota, K. Sano, N. Hirasawa, T. Terui, K. Ohuchi, T. Hattori, K. Shirato, and G. Tamura Novel Roles of CpG Oligodeoxynucleotides as a Leader for the Sampling and Presentation of CpG-Tagged Antigen by Dendritic Cells J. Immunol., July 1, 2001; 167(1): 66 - 74. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Shirota, K. Sano, T. Kikuchi, G. Tamura, and K. Shirato Regulation of Murine Airway Eosinophilia and Th2 Cells by Antigen-Conjugated CpG Oligodeoxynucleotides as a Novel Antigen-Specific Immunomodulator J. Immunol., June 1, 2000; 164(11): 5575 - 5582. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Todt, J. Sonstein, T. Polak, G. D. Seitzman, B. Hu, and J. L. Curtis Repeated Intratracheal Challenge with Particulate Antigen Modulates Murine Lung Cytokines ,2 J. Immunol., April 15, 2000; 164(8): 4037 - 4047. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Shirota, K. Sano, T. Kikuchi, G. Tamura, and K. Shirato Regulation of T-helper Type 2 Cell and Airway Eosinophilia by Transmucosal Coadministration of Antigen and Oligodeoxynucleotides Containing CpG Motifs Am. J. Respir. Cell Mol. Biol., February 1, 2000; 22(2): 176 - 182. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Crit. Care Med. |